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QUALITY OF LIFE AFTER SUBARACHNOID 
HEMORRHAGE IN RELATION TO RISK 
ESTIMATION BEFORE SURGERY
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1National Institute of Neurosurgery, Budapest, Hungary; 
2AstraZeneca, Törökbálint, Hungary
INTRODUCTION: Traditionally, long-term results of
neurosurgical interventions have been measured by the
Glasgow Outcome Scale. However, today, it is increas-
ingly important to assess health related quality of life
(HRQoL) as it is of utmost importance to the patients
and their families. The purpose of our study was to inves-
tigate the relationship between before operation risk esti-
mation and HRQoL one year after operation in patients
operated for cerebral aneurysms within 72 hours after
subarachnoid hemorrhage (SAH). METHODS: 97 pa-
tients underwent intracranial aneurysm surgery in the
National Institute of Neurosurgery in 1998. All patients
received nimodipine p os. The fluid therapy was guided
individually as the clinical signs and multimodal moni-
toring data indicated. The ASA physical status risk esti-
mator was assessed before surgery. 12 months after the
surgery, patients were interviewed by phone or by post.
Health status was measured as mortality and as HRQoL
measured by the EQ-5D questionnaire. ANOVA tests
were conducted. RESULTS: 6 out of the 97 patients were
lost during follow-up. Data of 91 patients (60 females
and 31 males) were finally analyzed. Mortality rate was
25,3%. 68 patients were alive one year after surgery. EQ-
5D weighted health status was 0.82, 0.55, 0.40 for pa-
tients with ASA scores of 1, 2, and 3, respectively (P 
0.021). Patients with ASA scores of 4 or 5 did not sur-
vive. Patients with intracerebral hemorrhage, ICH (25%)
had drastically lower HRQoL, 0.47 versus 0.70 (P 
0.042). CONCLUSION: Our study showed that ASA
risk estimation scores can well predict future HRQoL of
surviving patients. Patients who had an ASA value of 3
lived in worse HRQoL than people over eighty years of
age in the general population. Therefore, our results sug-
gest that pre-operation risk estimators should be care-
fully considered at clinical decisions and at subgroup
analyses in cost-effectiveness studies.
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OBJECTIVE: This is a cost-effectiveness analysis com-
paring one-year treatment of chronic non-malignant pain
with transdermal fentanyl and with sustained release
morphine. METHODS: A Markov-model was developed
which modeled the treatment as a recursive process of 12
monthly cycles. Effectiveness was defined as days with
good pain control. The following direct medical costs
were included: baseline treatment, breakthrough medica-
tion, concomitant medication and adverse event treat-
ment costs. Data on probabilities for altering pain con-
trol, for contracting adverse events, for switching treatment,
and resource use data were obtained from clinical trials
and from a Delphi panel. Unit costs were derived from
official tariff and price lists. Base-case analysis, one-way
and two-way sensitivity analyses were carried-out. RE-
SULTS: Effectiveness was 99 days with good pain con-
trol for the transdermal fentanyl treatment in compari-
son with 64 days for sustained release morphine. The
cost-effectiveness ratio (cost per day with good pain
control) was Euro 8.54 with transdermal fentanyl and
Euro 7.94 with sustained release morphine. The incre-
mental effectiveness of transdermal fentanyl was 35 days,
the incremental cost was Euro 338, and the incremental
cost-effectiveness was Euro 9.63. The costs of baseline
treatment, breakthrough and co-medication were higher,
the costs of adverse event treatment were lower with
transdermal fentanyl as compared with sustained mor-
phine. The sensitivity analyses did not greatly affect the
results and showed the model to be quite robust. CON-
CLUSION: Despite a cost-effectiveness ratio higher com-
pared to that of sustained release morphine, transdermal
fentanyl shows a valuable alternative for the treatment of
non-malignant chronic pain. The incremental cost-effec-
tiveness of transdermal fentanyl over sustained release
morphine is quite moderate and justified by its substan-
tially improved effectiveness with good pain control be-
ing a worth on its own, the higher patient preference due
to its simplified and more attractive route of administration.
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THE ATRIAL FIBRILLATION ANTITHROMBOSIS 
MODEL (AFAM): A GENERAL-PURPOSE TOOL 
FOR ANALYSIS, POLICY-MAKING,
AND EDUCATION
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OBJECTIVE: To develop a health and economic simula-
tion model of antithrombosis therapy that would serve as
a general-purpose tool for research planning, clinical trial
analysis, and education, and to demonstrate its use in a
